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Abstract
Self-expandable metallic stent (SEMS) placement is widely used for relieving symptoms in malignant gastric outlet obstruction
(MGOO). This study aimed to evaluate the efficacy and safety of multiple gastroduodenal stent placement using the stent-in-stent
technique and to identify factors predictive of stent patency.
We retrospectively analyzed data from 170 patients with GOO receiving SEMS using the stent-in-stent technique between July
2006 and July 2018. Of these, 90 had been treated with SEMS placement for MGOO. Technical and clinical success rates were
evaluated. Clinical outcomes and predictors of stent patency were also analyzed.
Second SEMS placement was used in 34.4% of cases and 9.7% were treated with third SEMS placement because of prior stent
dysfunction. Median stent patency time was 15.7 weeks for the first SEMS, 10.4 weeks for the second, and 11.3 weeks for the third.
The technical and clinical success rates were 100% and 97.8% for the first SEMS, 100% and 90.3% for the second, respectively, and
both 100% for the third. Multivariable analysis showed that use of covered SEMS and chemotherapy after first and second SEMS
placement was significant predictors of stent patency. Serious complications such as bleeding or perforation did not occur in any
patient.
Second and third gastroduodenal SEMS placement using the stent-in-stent technique is safe and effective for management of first
stent dysfunction in MGOO. Stent patency is significantly associated with the use of covered SEMS and chemotherapy after SEMS
placement.
Abbreviations: CT = computed tomography, GOO = gastric outlet obstruction, GOOSS = gastric outlet obstruction scoring
system, IQR = interquartile range, MGOO = malignant gastric outlet obstruction, SEMS = self-expandable metallic stent.
Keywords: malignant gastric outlet obstruction, predictive factor, self-expandable metallic stent, stent patency, stent-in-stent
technique
1. Introduction
Malignant gastric outlet obstruction (MGOO) is a late
complication of advanced gastrointestinal or pancreatobiliary
malignancies.[1] Prognoses of these advanced cancers are still
poor and the median overall survival is approximately 1 year.[2–4]
MGOO dramatically reduces the quality of life in patients with
limited life expectancy. Patients have nausea, vomiting, poor
appetite, intolerance to oral feeding, and weight loss.[5] It is
important to alleviate obstructive symptoms to improve the
quality of life in terminal patients.
Self-expandable metallic stent (SEMS) placement has been
widely used to relieve obstructive symptoms of MGOO and is
considered an alternative to surgical bypass such as gastro-
jejunostomy, especially in patients with a limited life span or
those in poor general condition.[6–8] The placement of a SEMS
has several advantages compared to surgical bypass, including
early time to oral intake, faster symptom relief, lower morbidity
andmortality, shorter hospital stay, and decreased cost.[7,9–11] As
a result of recent advances in cancer treatment, patients treated
with SEMS for MGOO can live longer than expected.[5] In these
cases, the SEMS is often clogged and requires second SEMS
placement.
Multiple SEMS placement is usually performed using a stent-
in-stent technique, which involves the insertion of a stent into the
stenotic portion of the prior stent.[12] Previous reports on
multiple gastroduodenal SEMS placement after first stent
dysfunction are limited. Therefore, our aim was to assess the
efficacy and safety of multiple gastroduodenal SEMS placement
using the stent-in-stent technique and to identify factors
predictive of stent patency.
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2. Materials and methods
2.1. Patient population
Between July 2006 and July 2018, 170 patients with gastric outlet
obstruction (GOO) underwent gastroduodenal SEMS placement
using a stent-in-stent technique. Of these, 90 had been treated
with gastroduodenal SEMS placement for MGOO. Gastroduo-
denal SEMS placement was performed at Gangnam Severance
Hospital in Seoul, Korea. Dysfunction of a prior stent was
confirmed endoscopically. Contraindications to multiple gastro-
duodenal SEMS placement were inability to tolerate the
endoscopic procedure due to poor general condition. Peritoneal
carcinomatosis and massive ascites were not considered contra-
indications to multiple gastroduodenal SEMS placement.
Informed consent was obtained from all patients before the
procedure. The study protocol conformed to the ethical guide-
lines of the World Medical Association Declaration of Helsinki
andwas approved by the Institutional Review Board of Gangnam
Severance Hospital (IRB No: 3-2018-0365).
2.2. Self-expandable metallic stent placement and follow-
up
Computed tomography (CT) and upper endoscopy were
performed to evaluate the obstruction site and stricture length
before SEMS placement. All SEMS placement was performed
using upper endoscopy through the working channels under
fluoroscopic guidance. The endoscope was carefully inserted near
the obstruction site and the causes of prior stent dysfunction were
evaluated endoscopically. A guidewire was passed through the
obstruction site and water-soluble radiographic contrast was
injected to identify the length and location of the obstruction. The
length of SEMS was determined by the stricture length, with an
additional 2 to 3cm on each side to ensure adequate margins after
placement.
Abdominal X-ray images were routinely taken after SEMS
placement to monitor SEMS expansion. Oral liquid intake was
allowed after the procedure and soft solids were allowed later.
Patients were permitted to eat a full diet as tolerated.
Chemotherapy including oral anticancer drug regimens and
radiotherapy were allowed after SEMS placement if the patients
remained in good general condition. If obstructive symptoms
recurred during follow-up, upper endoscopy and CT were
performed to evaluate the cause of obstruction. The next SEMS
was inserted to relieve obstructive symptoms using the stent-in-
stent technique.
2.3. Evaluation of the degree of gastric outlet obstruction
The degree of obstruction was assessed using the gastric outlet
obstruction scoring system (GOOSS).[13] Scoring is based on the
level of oral intake. For example, 0: no oral intake, 1: liquids only,
3: low-residue or full diet.
2.4. Definitions
Clinical outcomes of multiple gastroduodenal SEMS placement
were evaluated according to the following criteria:
(1) technical success,
(2) clinical success,
(3) status of oral intake evaluated with GOOSS,
(4) stent patency time,
(5) stent dysfunction,
(6) reintervention rate, and
(7) complications.
Technical success was defined as precise SEMS placement at
the obstruction site and adequate SEMS expansion. Clinical
success was defined as improvement in GOOSS score after SEMS
placement. Stent patency time was defined as the period between
SEMS insertion and SEMS restenosis. Stent dysfunction was
defined as recurrence of obstructive symptoms and failure to
resume oral intake. Causes of obstruction were classified as
ingrowth, overgrowth, fracture, or extrinsic obstruction on upper
endoscopic findings or fluoroscopic imaging. Complications were
monitored after SEMS placement.
2.5. Data collection
All data, including radiologic reports, procedure reports, and
blood biochemistry results, were obtained from medical records.
The retrospectively collected data included baseline character-
istics, primary cancer site, cancer stage, the presence of peritoneal
dissemination and ascites, chemotherapy/radiotherapy treat-
ment, GOOSS score, adverse events, and stent patency time.
This study was approved by the Institutional Review Board of the
Gangnam Severance Hospital.
2.6. Statistical analysis
Categorical variables were presented as a number (percentage).
The stent patency time was expressed as median ± Interquartile
Range (IQR) or actual range. Univariate analysis of stent patency
was analyzed with simple linear regression. Variables with P
values< .05 in univariate analysis were evaluated subsequently
with multivariate analysis. The multivariate analysis was
analyzed using multiple linear regression and the chi-squared
test. Statistical significance was defined as a P value< .05. An
improvement in GOOSS score after SEMS placement was
analyzed with the paired t test. SPSS ver. 23.0 for Windows
(SPSS, Chicago, IL) was used for all statistical analyses.
3. Results
3.1. Patient characteristics
Baseline characteristics are summarized in Table 1. The mean age
in our study group was 72.1 years, and 59 were males (65.6%).
Gastric cancer (73.3%) predominated, followed by pancreatic
cancer (12.2%) and cholangiocarcinoma (7.8%). These patients
were inoperable, with 82 (91.1%) already at stage IV. Peritoneal
carcinomatosis was present in 53 patients (58.9%) before the first
gastroduodenal SEMS placement and 27 (50.9%) had ascites.
Among these patients, 17 (18.9%) failed to resume any oral
intake.
3.2. Clinical outcomes
Table 2 shows the details after first SEMS placement. The pylorus
(54.4%) was the most common obstruction site in the stomach
and an uncovered SEMS (67.8%) was used more often than a
covered SEMS for initial placement. An 8cm long SEMS (33.3%)
was most frequently inserted in this population and the median
patency time for the first SEMS was 15.7 weeks (IQR 3–21
weeks). Technical success was achieved in all patients and clinical
success was attained in 88 (97.8%). After first SEMS placement,
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48patients (53.3%)were able to take a low-residue or full diet, and
the median GOOSS score was significantly improved from 1.06 to
2.54 (P< .001). Systemic chemotherapy was performed in 42
patients (46.7%) and 65 (72.2%) had peritoneal carcinomatosis.
Table 3 shows the details of second SEMS placement. First,
stent dysfunction was observed in 31 patients (34.4%). The
major indication was stent occlusion caused by tumor ingrowth
(77.4%) or overgrowth (12.9%). A covered SEMS (54.8%) was
used more often than an uncovered SEMS for second placement,
and the median patency time for the second SEMS was 10.4
weeks (IQR 1–13 weeks). Technical success was achieved in all
patients, with clinical success in 28 (90.3%). After second SEMS
placement, 18 patients (58.1%)were able to take a low-residue or
full diet, and the median GOOSS score was significantly
improved from 1.0 to 2.48 (P< .001). Systemic chemotherapy
was performed in 21 patients (67.7%).
3.3. Comparison of clinical outcomes after first, second,
and third SEMS placement
Comparison of clinical outcomes after first, second, and third
SEMS placement is shown in Table 4. Among 90 patients who
received first SEMS placement, 31 (34.4%) underwent second
SEMS placement for symptom relief. Among 31 patients who
received second SEMS placement, 3 (9.7%) underwent third
SEMS placement. Median stent patency time was 15.7 weeks for
Table 2
Clinical outcomes after first self-expandable metallic stent (SEMS)
placement.
n (%)













Median time of 1st stent patency (weeks, IQR) 15.7 (3–21)





Technical success 90 (100)
Clinical success 88 (97.8)














Age (year, mean) (range) 72.1 (31–96)
Primary cancer site
Gastric cancer 66 (73.3)
Pancreatic cancer 11 (12.2)
Cholangiocarcinoma 7 (7.8)







Peritoneal carcinomatosis 53 (58.9)





Chemotherapy before 1st SEMS placement
No 53 (58.9)
Yes 37 (41.1)
GOOSS=gastric outlet obstruction scoring system, SEMS= self-expandable metallic stent (SEMS).
Table 3
Clinical outcomes after second self-expandable metallic stent
(SEMS) placement.
n (%)




Extrinsic obstruction 2 (6.5)















Median time of 2nd stent patency (weeks, IQR) 10.4 (1–13)





Technical success 31 (100)
Clinical success 28 (90.3)
Chemotherapy after 2nd SEMS placement
No 21 (67.7)
Yes 10 (32.3)
GOOSS=gastric outlet obstruction scoring system, SEMS= self-expandable metallic stent (SEMS).
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the first SEMS, 10.4 weeks for the second, and 11.3 weeks for the
third. Technical success was achieved in all patients (100%) and
the clinical success rate was 97.8% for first SEMS, 90.3% for
second SEMS, and 100% for third SEMS. The mean GOOSS
scores were improved after first, second, and third SEMS
placement. Figure 1 shows endoscopic and fluoroscopic imaging
of patient who underwent first (A), second (B), and third (C)
SEMS placement. This 52-year-old male patient diagnosed with
advanced gastric cancer with partial GOO.
3.4. Factors predictive of stent patency
Univariate analysis showed that tumor origin and type of first
SEMS, chemotherapy after first SEMS placement, and compli-
cations were factors predictive of patency. However, in
multivariate analysis, only the type of SEMS and chemotherapy
after first SEMSplacementwere independent predictors (Table 5).
Univariate analysis showed that the type of second SEMS and
chemotherapy after second SEMS placement were predictive of
patency. Multivariate analysis showed that only chemotherapy
after second SEMS placement was significantly associated with
stent patency (Table 6).
4. Discussion
Endoscopic SEMS placement has been accepted as a safe and
effective palliative measure for MGOO that enables oral
intake.[14–16] SEMS placement has gradually replaced surgical
gastrojejunostomy for the treatment of MGOO.[17] A meta-
analysis of treatment using stents vs surgical gastrojejunostomy
reported in 2010 by Ly et al[18] showed that endoscopic stenting
was associated with increased tolerance of oral intake, shorter
time to initiation of oral intake, and shorter hospital stay after the
procedure.
However, obstructive symptoms can be problematic with first
stent dysfunction. Re-obstruction occurred in 13% to 26% of
Table 4
Comparison of clinical outcomes after first, second, and third self-expandable metallic stent (SEMS) placement.
1st SEMS 2nd SEMS 3rd SEMS
Number of patients (n, %) 90 (100) 31/90 (34.4) 3/31 (9.7)
Median stent patency time (weeks) (IQR or range) 15.7 (3–21) 10.4 (1–13) 11.3 (1–29)
Mean length of stent (cm) 8.89 9.61 10.66
Technical success (n, %) 90/90 (100) 31/31 (100) 3/3 (100)
Clinical success (n, %) 88/90 (97.8) 28/31 (90.3) 3/3 (100)
Mean GOOSS score
before stent placement 1.06 1.00 1.33
after stent placement 2.54 2.48 3
Chemotherapy after stent placement (n, %) 48/90 (53.3) 10/31 (32.3) 2/3 (66.6)
Complications 0 0 0
GOOSS=gastric outlet obstruction scoring system, SEMS= self-expandable metallic stent (SEMS).
Figure 1. Endoscopic and fluoroscopic imaging of patient who underwent first (A), second (B), and third (C) SEMS placement for MGOO. MGOO = malignant
gastric outlet obstruction, SEMS = self-expandable metallic stent.
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patients who underwent SEMS placement because of stent
dysfunction caused by tumor progression.[15,19] For patients who
experience stent dysfunction, additional SEMS placement is
usually required to correct for the loss of first stent patency.[20]
Second and third gastroduodenal SEMS placement is usually
performed using a stent-in-stent technique, which involves the
insertion of a stent into the stenotic portion of the prior stent.
Stent-in-stent technique is an effective treatment for patients with
MGOO who have occluded first stents.[12]
We analyzed the clinical outcomes of multiple gastroduodenal
SEMS placement. Among the 170 patients, 34.4% underwent
second SEMS placement and 9.7% underwent third SEMS
placement because of prior stent dysfunction. In this study,
multiple SEMS placement was safe and effective for obstructive
symptoms caused by dysfunction of first SEMS. The technical and
clinical success rates were 100% and 97.8% for the first SEMS,
100% and 90.3% for the second, respectively, and both 100%
for the third. These results were similar to those of previous
studies that reported technical success rates of 92% to 100% and
clinical success rates of 75% to 92% with palliative SEMS
placement in MGOO.[21–25] The mean GOOSS scores increased
after first SEMS placement as well as additional SEMS placement.
Themedian stent patency time was 15.7 weeks for the first SEMS,
10.4 weeks for the second, and 11.3 weeks for the third. These
results showed that the efficacy and safety of second and third
gastroduodenal SEMS placement were similar to those of first
SEMS placement. Sasaki et al[5] reported that the perforation rate
was higher after second stent placement than after first stent
placement (13.8% vs 0%; P= .02). However, there were no
procedure-related adverse events such as bleeding or perforation
after first, second, or third SEMS placement in our study.
We also identified factors predictive of stent patency. A few
studies of factors affecting stent patency have been published.
Telford et al reported that chemotherapy after stent insertion was
significantly associatedwith prolongation of oral intake.[26] Their
study was the first to assess the factors predictive of stent patency
in the treatment of inoperable MGOO through stent insertion.
Since then, other studies have reported similar results following
the use of chemotherapy.[23,27,28] Kim et al reported chemother-
apy to be a significant protective factor against restenosis.[28] In
Table 5
Univariate and multivariate analysis of first self-expandable metallic stent (SEMS) patency.
Univariate analysis Multivariate analysis
Variable n % P Odd ratio (95% CI) P
Tumor origin .019 .364
Non-gastric 66 73.3 .271 (.096–4.111)











Length of stenosis .351
6 cm 48 53.3
>6 cm 42 46.7





Chemotherapy before 1st SEMS placement .719
No 53 58.9
Yes 37 41.1
Type of 1st SEMS .000 .001
Uncovered 61 67.8 4.549 (5.15619.065)
Covered 29 32.2 Reference
Length of 1st SEMS .298
8 cm 51 56.7
>8 cm 39 43.3





Chemotherapy after 1st SEMS placement .001 .006
No 42 46.7 8.248 (2.73215.972)
Yes 48 53.3 Reference
GOOSS=gastric outlet obstruction scoring system, SEMS= self-expandable metallic stent (SEMS).
Mo et al. Medicine (2020) 99:21 www.md-journal.com
5
addition to chemotherapy, the stent type and type of malignant
obstructive lesion have been proposed as predictive of stent
patency.[23,29] However, other studies have reported that stent
type and the type of malignant obstructive lesion have no
significant association with stent patency.[30–32] Consequently,
this is an important subject for further investigation.[17]
In our multivariate analysis, covered SEMS and chemothera-
py after first and second SEMS placement were significant
predictors of stent patency. Performing chemotherapy after
SEMS placement may reduce or stabilize the tumor burden,
diminish tumor growth through the stent mesh, or overgrowth
at the stent edges, and prolong the duration of oral intake.[17,20]
The patients who received chemotherapy had better perfor-
mance status and longer stent patency than those who did not. A
covered SEMS may have a more favorable outcome than an
uncovered stent in the treatment of GOO caused by primary
gastrointestinal cancer.[23] Moreover, a covered SEMS can
extend stent patency by reducing the risk of stent obstruction
due to tumor ingrowth or mucosal hyperplasia.[33] However,
there is no consensus regarding the use of covered SEMS to treat
GOO because only a few prospective randomized comparison
studies have been reported. Therefore, the choice of covered or
uncovered SEMS depends on the operator’s preference or lesion
characteristics.[25]
The first stent patency was related to both covered SEMS and
chemotherapy after placement, but the second stent patency was
related only to chemotherapy after SEMS placement. This
suggests that it may be important to reduce the tumor burden
with chemotherapy rather than changing the stent type as the
number of stents increases. This is because stent patency becomes
more consistent with survival over time.
Our study had several limitations. First, this was a single-center
studywith a small sample size. Second, this studywas conducted in
a retrospective manner, and SEMS patency was assessed with
GOOSS instead of second-look endoscopy, which was only
performed for selected patientswho experienced stent dysfunction.
Third, SEMS placements were performed by several different
endoscopists. Fourth, various malignancies with different progno-
ses may influence SEMS patency, particularly with addition of
chemotherapy.
In conclusion, second and third gastroduodenal SEMS
placement using the stent-in-stent technique is safe and effective
for first SEMS dysfunction in MGOO. Patency is significantly
associated with the use of covered SEMS and chemotherapy after
SEMS placement.
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